Saturday 17 October 2026
Export BTCY’s income statement to Excel — free account
Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
0.05
0.00
0.00%
Follow BTCY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 9.75% | 9.38% | 14.19% | 15.07% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 5 | 4 | 5 | |
| (57.12%) | (51.76%) | (80.47%) | (83.81%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
10.85% | 10.00% | 24.97% | 26.93% | |
Average Days of Receivables |
53.36 | 66.91 | 37.29 | 50.80 | |
Free Cash Flow per Share |
0.01 | (0.03) | (0.04) | (0.02) | |
Free Cash Flow |
0.16 | (0.72) | (1.10) | (0.45) | |
| Other line items | |||||
Cash ROIC |
(1.96%) | 9.15% | 14.78% | 6.02% | |
Accounts Receivable Turnover |
7.70 | 6.97 | 10.98 | 8.38 | |
Accounts Payable Turnover |
0.35 | 0.37 | 0.35 | 0.36 | |
Inventory Turnover |
1.89 | 2.11 | 1.65 | 1.49 | |
Average Days of Payables |
1,117.44 | 1,073.78 | 1,065.81 | 949.19 | |
Days of Inventory on Hand |
171.19 | 160.55 | 246.66 | 270.82 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
16.72% | 17.28% | 16.15% | 16.06% | |
Selling, General and Administrative Expense of Revenue |
55.20% | 53.09% | 64.02% | 66.88% | |
Share Based Compensation of Revenue |
2.22% | 0.18% | 10.09% | 10.59% | |
Interest Coverage |
0.47 | 0.50 | 0.04 | (0.14) | |
Operating CF/Net income |
(0.05) | 0.23 | 0.23 | 0.09 | |
Depreciation/Fixed assets |
368.32 | 208.83 | 147.59 | 123.77 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.71 | 0.59 | 0.56 | 0.56 | |
Operating CF per Share |
0.01 | (0.03) | (0.04) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 28 Sep 2026